Weei/nesn Jimmy Fund Radio-telethon

Two miles there and two miles back. That’s the distance John Warner would walk from his Back Bay home to Dana-Farber to keep himself in shape while in treatment for renal cell carcinoma, or kidney cancer. John was diagnosed in the winter of 2021. John experienced blood in his urine which led to a scan at his physical. That scan revealed a tumor between one of his kidneys and ureters that was promptly removed. He consulted several top medical centers around the country before ultimately undergoing a chemotherapy plan with Dana-Farber. He was cancer-free after six months, until it returned three months later. John pivoted to immunotherapy treatment under the care of Dr. Toni Choueiri for several months before joining a chemotherapy clinical therapy exclusive to Dana-Farber patients.  John stayed on the trial for 16 months and just came off it a few months ago. He’s continued to work as a Senior Partner at McKinsey and Company throughout his treatment, while also doing activities he loves like playing golf and g

 Craig Bunnell, MD, MPH, MBA, is the Morse Family Chief Medical Officer of the Dana-Farber Cancer Institute, an NCI-designated Comprehensive Cancer Center and Harvard Medical School-affiliated teaching hospital. In this role, Dr. Bunnell oversees adult and pediatric clinical services at Dana-Farber. Under his leadership, the Institute has become a leader in implementing technology to enhance patient flow, operational efficiency, and patient access.  Dr. Bunnell is also a breast medical oncologist at Dana-Farber and an Associate Professor of Medicine at Harvard Medical School. He has been the principal investigator of several institutional and multicenter clinical trials and serves on several editorial boards.  Dr. Bunnell received his MD from Harvard Medical School, MPH from the Harvard School of Public Health, MBA from the Massachusetts Institute of Technology. He completed his medical training at Brigham and Women's Hospital where he also served as Chief Medical Resident.  Dr. Bunnell has more than 120 orig

 Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.  In September 2020, amid downsizing to a forever home with her husband, Barbara Ackerman, was diagnosed with stage 4 lung cancer.  After experiencing persistent back pain, a chiropractor suggested an x-ray, leading her to consult her doctor. She knew she wanted to be treated at Dana-Farber due to its reputation, and Dr. Janne, a specialist in EGFR, was highly recommended. Doctors f

 In June 2018, Gloria was playing golf when she realized something was wrong. Her primary care doctor was alarmed when Gloria asked to bump up her physical and arranged for an immediate appointment and blood tests, which revealed she had Acute lymphocytic leukemia. · Referred to Dana-Farber by her son, a physician, Gloria began a grueling chemotherapy regimen, sometimes undergoing treatment for 21 hours a day. Undeterred, she requested a stationary bike for her room and continued to walk - even while attached to IV poles. Her determination paid off, and after becoming cancer-free, Gloria underwent a stem cell transplant in December 2018, with a donor from California. But her journey didn't end there. A few years later during a winter vacation in Florida, doctors discovered her cancer returned. This time, she underwent Dana-Farber’s innovative CAR T therapy and was once again deemed cancer-free.· Throughout her cancer journey, Gloria remained active and engaged, chatting with nurses about fashion—she owned a w

The Dubowik household came down with the flu. While everyone else recovered, Evelyn got worse and had “bizarre” bruising. Her mother took her to the emergency room for difficulty breathing. After some lab work, doctors discovered she had cancer.· Evelyn is in a two-year treatment plan and went from “standard risk” to “high risk” when she didn’t hit remission when she was supposed to. This meant giving her a stronger chemotherapy regimen. Today, Evelyn is in remission and is set to finish her treatments at the start of 2025. · When she’s at The Jimmy Fund Clinic, Evelyn loves the people there, crafts, the decorations, music therapy, and Opry the facility dog. Evelyn will be in first grade and is home-schooled. She loves to swim, do acrobats, dance, and sing. Evelyn is a hard-core Swiftie and one of Taylor Swift’s biggest fans. 

Nine years ago, Joel was diagnosed with prostate cancer at his annual wellness exam while living in Connecticut; his best friend was his urologist at the time. He began making regular visits to Boston to get treated at Dana-Farber. Dr. Mark Pomerantz is a medical oncologist and Clinical Director for the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women's Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology at Dana-Farber. Dr. Pomerantz received his post-doctoral training in cancer genetics with Dr. Matthew Freedman at Dana-Farber and the Broad Institute of Harvard and MIT. He also teaches as an Assistant Professor of Medicine at Harvard Medical School. 

Paul Mossberg, 58, esophageal cancer, Brookline, with Melissa Levin, MSW, LICSW, Senior Clinical Social Worker and Programmatic Specialist for the Neuro-Inclusive Oncology Care and Empowerment Program, Dana-Farber.

  Dr. Meyerhardt is the Chief Clinical Officer for Dana-Farber and Co-Director of the Colon and Rectal Cancer Center as a medical oncologist specializing in cancers in the GI tract. He is also the Douglas Gray Woodruff Chair in Colorectal Cancer Research and a Professor of Medicine at Harvard Medical School.       Dr. Meyerhardt received his MD from Yale School of Medicine in 1997. He completed a residency in internal medicine at Beth Israel Deaconess Medical Center, in Boston, followed by a medical oncology fellowship at DFCI. He joined the Gastrointestinal Cancer Center at Dana-Farber in 2002.  

  Anne Gross, PhD, RN, FAAN, is senior vice president for patient care services and chief nursing officer. Dr. Gross is responsible for adult and pediatric nursing practice across all sites of care at Dana-Farber Cancer Institute, The Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, and the Center for Clinical and Professional Development. She also oversees a variety of other clinical services, patient and family programs, and Volunteer Services.       Since joining Dana-Farber in 2002, she has led implementations of a primary nursing care model and a residency training program for newly licensed nurses, and secured funding for programs and research to support inclusion, diversity and equity, positive practice environments, and self-care and renewal programs. She also is involved in committees, boards, and initiatives nationally and internationally and is a Fellow in the American Academy of Nursing.       Dana-Farber continues to grow, and Nursing and Patient Care Services is conti

Lisa Scherber talks about what the first day of the Jimmy Fund Telethon has been like so far and the stories that have touched her the most.

Arbella Insurance Vice President Gayle O'Connell brings a BIG donation check for the Jimmy Fund Radio Telethon.

Laurie H. Glimcher, MD, was named President and CEO of Dana-Farber CancerInstitute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. A trailblazer in cancer research, Dr. Glimcher's research identified keytranscriptional regulators of protective immunity and the origin of pathophysiologicimmune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to medical literature. Aside from her research efforts, Dr. Glimcher has been a s

In early 2020, it became difficult for Clinton to eat. It was during the pandemicand much harder at the time to see a doctor, so it took a while before he was able to get checked out. In January 2021, Clinton was diagnosed with esophageal cancer that metastasized into his lungs. His treatment included six months on a feeding tube, chemotherapy and radiationtreatments. In summer 2021, he received an esophagectomy and now comes in forchemotherapy every other week. He will continue these sessions for the foreseeablefuture. The American Cancer Society estimates that there will be about 22,370 newesophageal cancer cases diagnosed (17,690 in men and 4,680 in women) in 2024. Esophageal cancer is more common among men than among women. Thelifetime risk of esophageal cancer in the United States is about 1 in 127 in men andabout 1 in 434 in women.

Red Sox legend and Hall of Famer Carlton Fisk talks about the long-time support he has given to the Jimmy Fund and how Fenway has changed since his playing days.

Dr. Hartley-Brown's clinical area of focus is treating patients with MultipleMyeloma. This is an incurable blood cancer, that affects African Americans moreprevalently than other ethnic populations. She also practices clinical research, mainly in the relapsed refractory myeloma disease setting. Dr. Hartley-Brown actively participates as a principal investigator in clinical trials within the Alliance for Clinical Trials, investigator-initiated and investigator sponsored trials. Her area of interest in clinical trials includes use of immunotherapies and targeted therapies, such asbispecific/tri-specific antibodies, antibody-drug conjugates and modern immunemodulating drugs (ex. cereblon modulators).

Jaimey was diagnosed with prostate cancer in 2008. He was treated and received a clean bill of health and remained cancer-free. In May 2015, a routine blood donation led to a life-changing discovery when the Red Cross director urged him to seek immediate medical attention. Jaimey was diagnosed with chronic lymphocytic leukemia (CLL), which, contrary to its typical slow progression, advanced rapidly in his case. Jaimey remained active, cycling and running to maintain his mental well-being.However, six to nine months ago, his CLL numbers began to rise again, promptingdiscussions about future treatments. Although his white blood cell count is high and he has low antibodies, making illnesses particularly severe, Jaimey remains optimistic with Dana-Farber's support. After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davidscompleted his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at NewYork-Presbyterian

Erica Howes is joined by patient Sophia and her daughter Alice to share that Howes will be making a big donation to the Jimmy Fund.

Brock Holt nicknamed, “The Brock Star” is a former Major League Baseball utilityplayer who played for the Boston Red Sox (2013–2019). He served as the Jimmy Fund Captain from 2015-2019 and has been a long-time supporter of Dana-Farber’s fundraising efforts. After serving as Jimmy Fund Captain, Holt and Lakyn have remained steadfastsupporters of Dana-Farber and the Jimmy Fund. They ran the Boston Marathon ®for the Dana-Farber Cancer Institute Marathon Challenge in 2023, sold t-shirts to raise funds for the Jimmy Fund Clinic, where pediatric patients receive care, and have participated in many Jimmy Fund Clinic patient events, virtually and in person, always focused on promoting the work at Dana-Farber. Melany Duval is the Senior Vice President and Chief Philanthropy Officer atDana-Farber Cancer Institute and responsible for the fundraising strategy and tactics in the Division of Philanthropy; including The Dana-Farber Campaign. Duval is a seasoned development executive with over three decades of experience in

Matt Waning's cancer journey began in 2021, at the age of 34, when he wasdiagnosed with testicular cancer. The aggressive nature of his illness led to surgery that removed a tumor the size of a watermelon, along with his left testicle and kidney, as the tumor had reached his aorta. Following surgery, he underwent two months of preventive chemotherapy known as VIP treatment and celebrated being in remission by August 2021. However, the VIP treatment came with a rare side effect—a potential risk of developing acute myeloid leukemia (AML). Unfortunately, in January 2023, Matt was diagnosed with AML as a result of the chemotherapy he had previously received. Matt is an avid Boston sports fan, with a particular passion for the Bruins. Musicis another love of his, offering solace and joy throughout his journey. As the oldest of three siblings, he shares a special bond with his family, including his dog Mogley, named after the main character from "The Jungle Book." Dr. Stone is currently the Director of the Adult Ac

Dr. Cutler received his MD from McGill University, Montreal, Canada. Hesubsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff. Dr. Cutler is a Director of the Adult Cell Transplantation Program, Director of ClinicalResearch for Stem Cell Transplantation and Director of the Stem Cell TransplantationSurvivorship Program. He also works as an Associate Professor of Medicine at Harvard Medical School.